A retrospective multicentric observational study assessing the efficacy of immunotherapy in terms of survival and response to treatment as second- or third-line therapy in Hispanic patients with advanced non-small cell lung cancer
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology